Effectively Targeting Burkitt Lymphoma By Anti-CD20 Chimeric Antigen Receptor (CAR) Modified Expanded Natural Killer Cells Combined with a Histone Deacetylase Inhibitor, Romidepsin in Vitro and In Humanized NSG Mice

被引：2
|
作者：
Chu, Yaya [1 ]
Yahr, Ashlin [1 ]
Ayello, Janet [1 ]
Cairo, Mitchell S. [1 ]
机构：
[1] New York Med Coll, Valhalla, NY 10595 USA
来源：
BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION | 2015年 / 21卷 / 02期
关键词：
D O I：
10.1016/j.bbmt.2014.11.216
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
181
引用
收藏
页码：S152 / S153
页数：2
相关论文
共 45 条
  • [31] Clinical results of a first-in-human phase 1 study Bispecific anti-CD19, ANTI-CD20 chimeric antigen receptor modified (LV20.19CAR) T cells for relapsed, refractory, non-Hodgkin lymphoma
    Shah, Nirav
    Zhu, Fenlu
    Keever-taylor, Carolyn
    Schneider, Dina
    Kruger, Winfried
    Worden, Andrew
    Hamadani, Mehdi
    Fenske, Timothy
    Johnson, Bryon
    Dropulic, Boro
    Orentas, Rimas
    Hari, Parameswaran
    [J]. BONE MARROW TRANSPLANTATION, 2019, 54 : 123 - 124
  • [32] Regulation of the Functions of Expanded Natural Killer (NK) Cells by N-820, an IL-15 Superagonist with 4 Single-Chain Anti-CD20 Antibody Domains Against Burkitt Lymphoma (BL)
    Chu, Y.
    Nayyar, G.
    Rosenblum, J.
    Jeng, E.
    Rhode, P.
    Lee, D.
    Wong, H.
    Lee, J.
    Cairo, M.
    [J]. PEDIATRIC BLOOD & CANCER, 2019, 66 : S426 - S426
  • [33] Clinical Results of a First-in-Human Phase 1 Study of Point-of-Care Manufactured Bispecific Anti-CD19, Anti-CD20 Chimeric Antigen Receptor Modified T (CAR-20.19-T) Cells for Relapsed, Refractory, Non-Hodgkin Lymphoma (NHL)
    Shah, Nirav N.
    Zhu, Fenlu
    Keever-Taylor, Carolyn
    Schneider, Dina
    Kruger, Winfred
    Worden, Andrew
    Hamadani, Mehdi
    Fenske, Timothy S.
    Johnson, Bryon D.
    Dropulic, Boro
    Orentas, Rimas
    Hari, Parameswaran
    [J]. BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION, 2019, 25 (03)
  • [34] Significant Targeting of Neuroblastoma By Anti-ROR1 Chimeric Antigen Receptor (CAR) Engineered NK Cells with or without IL-15 Superagonist (N-803) in Vitro and In Vivo Using Human Neuroblastoma Xenografted NSG Mice
    Chu, Yaya
    Nayyar, Gaurav
    Wong, Hing C.
    Seeger, Robert C.
    Lee, John H.
    Riddell, Stanley R.
    Safrit, Jeffrey
    Lee, Dean
    Cairo, Mitchell S.
    [J]. BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION, 2020, 26 (03) : S256 - S256
  • [35] A Phase 1 Study with Point-of-Care Manufacturing of Dual Targeted, Tandem Anti-CD19, Anti-CD20 Chimeric Antigen Receptor Modified T (CART-T) Cells for Relapsed, Refractory, Non-Hodgkin Lymphoma
    Shah, Nirav N.
    Zhu, Fenlu
    Taylor, Carolyn
    Schneider, Dina
    Krueger, Winfried
    Worden, Andrew
    Yim, Sharon
    Fenske, Timothy S.
    Hamadani, Mehdi
    Johnson, Bryon
    Dropulic, Boro
    Orentas, Rimas
    Hari, Parameswaran
    [J]. BLOOD, 2018, 132
  • [36] TARGETING EWING SARCOMA WITH ANTI-IL1RAP CHIMERIC ANTIGEN RECEPTOR MODIFIED EX-VIVO EXPANDED NATURAL KILLER CELLS (IL1RAP-CAR NK) AND TGF-BETA IMPRINTED NK CELLS (CAR TGFBI-NK) IN COMBINATION WITH DINUTUXIMAB AND NKTR-255
    Luo, Wen
    Zhang, Hai-Feng
    Hoang, Hai
    Chu, Yaya
    Ayello, Janet
    Li, Wei
    Scopim-Ribeiro, Renata
    Lizardo, Michael M.
    Rouleau, Melanie
    Dimitrov, Dimiter S.
    Lee, Deana.
    Sorensen, Poul H.
    Cairo, Mitchell S.
    [J]. PEDIATRIC BLOOD & CANCER, 2023, 70 : S205 - S206
  • [37] CD19-Chimeric Antigen Receptor (CAR) Engineered Natural Killer (NK) Cell Therapy: Novel "Off the Shelf" Immunotherapy in CD20 Resistant B-Cell Non-Hodgkin Lymphoma (NHL) Cell Lines, Primary NHL Cells, and a Human Lymphoma Xenograft Model
    Purvey, Sneha
    Dashnamoorthy, Ravi
    Beheshti, Afshin
    Klein, Andreas
    Boissel, Laurent
    Sarkar, Saheli
    Konry, Tali
    Evens, Andrew M.
    [J]. BLOOD, 2017, 130
  • [38] 2B8T2M, a novel fusion of ALT-803, an IL-15 superagonist, with 4 single-chains of anti-CD20 Antibody significantly enhanced expanded natural killer cells cytotoxicity against rituximab sensitive and resistant Burkitt lymphoma (BL)
    Chu, Yaya
    Su, Nang Kham
    Jeng, Emily K.
    Alter, Sarah
    Rhode, Peter R.
    Nayyar, Gaurav
    Barth, Mathew
    Lee, Dean A.
    Wong, Hing C.
    Cairo, Mitchell S.
    [J]. BRITISH JOURNAL OF HAEMATOLOGY, 2018, 182 : 46 - 47
  • [39] Therapeutic Effects of a Novel Fusion of ALT-803, an IL-15 Superagonist, with 4 Single-Chains of Anti-CD20 Antibody (2B8T2M) in Combination with Expanded Natural Killer Cells Against Rituximab Sensitive and Resistant Burkitt Lymphoma (BL)
    Chu, Yaya
    Su, Nang Kham
    Alter, Sarah
    Jeng, Emily K.
    Rhode, Peter R.
    Barth, Matthew
    Lee, Dean
    Wong, Hing C.
    Cairo, Mitchell S.
    [J]. BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION, 2018, 24 (03) : S75 - S76
  • [40] THERAPEUTIC EFFECTS OF A NOVEL FUSION OF ALT-803, AN IL-15 SUPERAGONIST, WITH 4 SINGLE-CHAINS of ANTI-CD20 ANTIBODY (2B8T2M) IN COMBINATION WITH EXPANDED NATURAL KILLER CELLS AGAINST RITUXIMAB SENSITIVE AND RESISTANT BURKITT LYMPHOMA (BL)
    Chu, Yaya
    Su, Nang Kham
    Alter, Sarah
    Jeng, Emily K.
    Rhode, Peter R.
    Barth, Mathew
    Lee, Dean A.
    Wong, Hing C.
    Cairo, Mitchell S.
    [J]. PEDIATRIC BLOOD & CANCER, 2018, 65
12345